Anavex Life Sciences Corp. (AVXL) |
|
11.89 0.53 (4.67%)
|
11-25 13:00 |
|
Open: |
11.3 |
Pre. Close: |
11.36 |
|
High:
|
11.95 |
Low:
|
11.27 |
|
Volume:
|
778,695 |
Market Cap:
|
927(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:55:20 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.89 One year: 17.8 |
| Support: |
Support1: 10.97 Support2: 9.12 |
| Resistance: |
Resistance1: 13.6 Resistance2: 15.23 |
| Pivot: |
12.56 |
| Moving Average: |
MA(5): 11.75  MA(20): 12.44
MA(100): 11.04 MA(250): 11.54 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 13.7 %D(3): 13.7 |
| RSI: |
RSI(14): 48.1 |
| 52-week: |
High: 20.23 Low: 7.13 |
| Average Vol(K): |
3-Month: 892 (K) 10-Days: 1,133 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVXL ] has closed above bottom band by 34.3%. Bollinger Bands are 57.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.9 - 12.01 |
12.01 - 12.08 |
|
Low:
|
10.87 - 11.01 |
11.01 - 11.1 |
|
Close:
|
11.19 - 11.43 |
11.43 - 11.57 |
|
Company Description |
|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. |
Headline News |
Fri, 25 Nov 2022
Pre-Market Earnings Report for November 28, 2022 : PDD, HTHT, AVXL - Nasdaq
Wed, 23 Nov 2022
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St
Tue, 22 Nov 2022
Anavex Life Sciences (AVXL) is scheduled to report quarterly earnings on Tuesday. - Best Stocks
Mon, 14 Nov 2022
Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback - Seeking Alpha
Fri, 11 Nov 2022
Anavex Life Sciences Corp (AVXL) Stock: What Does the Chart Say Friday? - InvestorsObserver
Tue, 08 Nov 2022
Anavex Life Sciences Corp (NASDAQ: AVXL) On Watch as Biotech to Present Results for its Phase 2b/3 Trial for blarcamesine for Alzheimer’s Disease - MicroCap Daily
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
78 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
3 (%) |
|
% Held by Institutions
|
32.1 (%) |
|
Shares Short
|
10,110 (K) |
|
Shares Short P.Month
|
10,260 (K) |
Stock Financials |
|
EPS
|
-0.58 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-17.1 |
|
Return on Equity (ttm)
|
-29.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-28 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-20.51 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.16 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-33.26 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
